Hmm..
"
On 28 October 2013, Invion announced it had entered a licence agreement with Accolade Pharma LLC for an exclusive, worldwide licence to develop and commercialise all inhaled formulations and applications of zafirlukast. A licence fee of $500,000 was payable by Invion to Accolade Pharma LLC over a 12 month period commencing January 2014. Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC. "
- Forums
- ASX - By Stock
- Ann: Notice under Section 708A
Hmm.. " On 28 October 2013, Invion announced it had entered a...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IVX (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $26.41M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.4¢ | $41 | 10.22K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 10821159 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 8373283 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 10821159 | 0.004 |
20 | 14450755 | 0.003 |
5 | 4900000 | 0.002 |
8 | 13200000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 8373283 | 29 |
0.006 | 3871276 | 12 |
0.007 | 3518975 | 7 |
0.008 | 4842200 | 6 |
0.009 | 2650299 | 8 |
Last trade - 15.36pm 16/07/2024 (20 minute delay) ? |
Featured News
IVX (ASX) Chart |